30 closest matches · ranked by relevance
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Leukemia · Lymphoma
Primary: Number of Transplant Recipients With Successful Engraftment — 70 Participants
Dyskeratosis Congenita · Aplastic Anemia
Primary: Incidence of Neutrophil Engraftment — 100; 100; 96; 100 Percentage of participants
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
Hematopoietic/Lymphoid Cancer
Primary: Count of Participants That Experience 1 Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Using the Thomas Jefferson University…
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Day 100 TRM — 4 Participants
Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count >= 500/Mcl for 3 Consecutive Measurements on Different Days and Platelet Count > 20,000/mm^3 With no Platelet…
Blood Cancer · Leukemia · Graft Versus Host Disease
Primary: Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and…
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Hematologic Malignancies · Bone Marrow Transplant Rejection
Primary: The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30 — 44.9 percentage of participants
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Hematologic Malignancies
Primary: Disease-free Survival (DFS) — 57; 29; 38; 57 percentage of participants
Myeloablative Conditioning · HLA-mismatched Bone Marrow Transplantation · Graft Survival
Primary: Cumulative Incidence of Non-relapse Mortality — 0 percent
Hematologic Malignancies · Disorder Related to Transplantation · Hematopoietic Malignancy
Primary: Event Free Survival (EFS) for Research Participants — 4 Participants
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Survival Rate at Day 100 After Allogeneic Transplant From Umbilical Cord Blood (UCB) — 100; 100; 100 percentage of surviving patients
Hematopoietic Steam Cell Transplantation (HCT)
Primary: Change in Physical Function, as Measured by 6 Minute Walk Test (6MWT) — 449; 468; 478 meters
Chronic Leukemia · Acute Leukemia · Hodgkin's Disease
Primary: Percentage of Patients Experiencing Hemorrhagic Cystitis Post Transplant — 30 percentage of patients
Leukemia · Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count Engraftment — 21 participant
Acute Myeloid Leukemia With FLT3/ITD Mutation · Acute Myeloid Leukemia With Gene Mutations · Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM
Primary: Disease-free Survival (DFS) — .5 proportion of participants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
Hematologic Diseases
Primary: Caregiver Health-related Quality of Life (HRQOL) Assessed by the PROMIS Global Health Scale. — 48.18; 48.16 score on a scale
Acute Myeloid Leukemia · Acute Lymphocytic Leukemia · Myelodysplasia
Primary: One-year Survival — 50 percentage of participants
Malignant Diseases · Non-malignant Diseases
Primary: Number of Patients With Severe (Grade III/IV) Acute Graft vs Host Disease (GVHD) — 0 Participants
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Biphenotypic Acute Leukemia
Primary: Disease Free Survival — 70.6 percentage of participants — p=0.002
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Graft Rejection — 3 Participants
Allogeneic Stem Cell Transplant · Leukemia · Non-Hodgkins
Primary: Overall Survival of Transplant Patients — 727.5 Days
Lysosomal Storage Disease · Peroxisomal Disorder
Primary: Donor (Allogeneic) Hematopoietic Engraftment — 1 participants
Leukemia · Lymphoma · HIV
Primary: Percentage of Participants With Non-Relapse Mortality — 0.0; 11.8; 18.3 percentage of participants
Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia · Burkitt's Lymphoma
Primary: Percentage of Participants With Progression Free Survival (PFS) — 35.0; 41.1 percentage of participants — p=0.4092